Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Kesimpta
| Field | Information |
|---|---|
| Medication Name | Kesimpta |
| Generic Name | Ofatumumab |
| Purpose | Treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. |
| Mechanism of Action | Binds to CD20, a protein expressed on B cells, leading to B cell depletion. |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 20 mg/0.4 mL |
| Dosage Frequency | Initial doses at weeks 0, 1, and 2, then once monthly thereafter. |
| Common Side Effects | Injection-related reactions (e.g., fever, headache, muscle pain), upper respiratory tract infection, urinary tract infection. |
| Serious Side Effects | Infections (including progressive multifocal leukoencephalopathy (PML)), reduced immunoglobulin levels, hypersensitivity reactions. |
| Drug Interactions | Immunosuppressants, live or live-attenuated vaccines. |
| Important Notes | Monitor for signs of infection. Avoid vaccinations during treatment. Women of childbearing potential should use contraception during treatment and for 6 months after the last dose. |
| Storage | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Administer as soon as possible without waiting until the next scheduled dose. Maintain a 4-week interval between doses. |
| Alternatives | Ocrevus (ocrelizumab), Gilenya (fingolimod), Aubagio (teriflunomide), Tysabri (natalizumab). |
Kesimpta Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Ocrevus (ocrelizumab) | Binds to CD20+ B cells, causing cell lysis. | Administered as an intravenous infusion every 6 months. |
| Gilenya (fingolimod) | Sphingosine 1-phosphate receptor modulator. | Oral medication taken once daily. |
| Aubagio (teriflunomide) | Pyrimidine synthesis inhibitor. | Oral medication taken once daily. |
| Tysabri (natalizumab) | Alpha-4 integrin antagonist. | Administered as an intravenous infusion every 4 weeks. Higher risk of PML. |
Kesimpta Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Injection-related reactions (fever, headache, muscle pain) | Infections (including PML) |
| Upper respiratory tract infection | Reduced immunoglobulin levels |
| Urinary tract infection | Hypersensitivity reactions (rash, itching, swelling, difficulty breathing) |
| Headache | Hepatitis B virus reactivation |
Kesimpta Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Relapsing Forms of Multiple Sclerosis | 20 mg at Weeks 0, 1, and 2 | 20 mg monthly, starting at Week 4 | Administer as a subcutaneous injection. Rotate injection sites. |
Kesimpta Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $7,500 |
| Without Insurance (U.S.) | $8,500 |
| From Canada | $6,500 |
